IFNG and neoplasm: Further, we found that 4MOSC1-LucOS tumor-bearing animals having experienced a complete response to αCTLA-4 ICI therapy harbor OVA-Tet+ CD8 T cells that respond robustly to rechallenge with SIINFEKL-loaded bone marrow-derived dendritic cells, as assessed by IFNγ ELISpot assays (Supplementary Fig 3I, J).